{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T04:08:58Z","timestamp":1749182938458,"version":"3.41.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>To determine the level of vascularization and peripheral vascular findings by fluorescence angiography in patients with aggressive retinopathy of prematurity or Type 1 retinopathy of prematurity treated with a single dose of anti\u2013vascular endothelial growth factor.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Data of patients referred to the authors' clinic for fluorescence angiography examination between June 2016 and September 2021 were retrospectively analyzed. Patients who had their first fluorescence angiography examination at the age of 1 year or older were included in the study.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 486 eyes of 250 patients were included. Of these, 83 eyes (17.1%) had vascular termination in Zone II and 403 eyes (82.9%) in Zone III. In 62.7% of eyes, the distance from the vascular terminals to the temporal ora serrata was less than two disk diameters, and in 20.2%, it was more than two disk diameters. Abnormal vascular findings were noted, including circumferential vessels (41.2%), finger-like projection anomaly (36.2%), hyperfluorescence (16.9%), fine branching and blunt termination (15%), and arteriovenous shunt (9.9%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Fluorescence angiography performed late in the course of treatment can clearly define the vascular termini and detect abnormalities that cannot be detected by indirect ophthalmoscopy. Follow-up with fluorescence angiography can help prevent complications that can lead to vision loss.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/iae.0000000000004032","type":"journal-article","created":{"date-parts":[[2023,12,27]],"date-time":"2023-12-27T21:02:32Z","timestamp":1703710952000},"page":"901-908","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["FLUORESCEIN ANGIOGRAPHY EVALUATION OF CHILDREN PREVIOUSLY TREATED WITH ANTI\u2013VASCULAR ENDOTHELIAL GROWTH FACTOR MONOTHERAPY FOR RETINOPATHY OF PREMATURITY"],"prefix":"10.1097","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9460-2501","authenticated-orcid":false,"given":"Fatma","family":"Poslu Karademir","sequence":"first","affiliation":[{"name":"Beyoglu Eye Training and Research Hospital, University of Health Sciences, Istanbul, Turkey; and"},{"name":"Department of Ophthalmology, University of Health Sciences Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asl\u0131","family":"Vural","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Health Sciences Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet","family":"\u00d6zba\u015f","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Health Sciences Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bengi","family":"Demirayak","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Health Sciences Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250605","first-page":"233","article-title":"Final results of the early treatment for retinopathy of prematurity (ETROP) randomized trial","volume":"102","author":"Good","year":"2004","journal-title":"Trans Am Ophthalmol Soc"},{"key":"R2-20250605","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000364809","article-title":"Structural, visual and refractive outcomes of intravitreal aflibercept injection in high-risk prethreshold type 1 retinopathy of prematurity","volume":"53","author":"Salman","year":"2015","journal-title":"Ophthalmic Res"},{"key":"R3-20250605","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"New Engl J Med"},{"key":"R4-20250605","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.earlhumdev.2012.09.019","article-title":"Treatment of retinopathy of prematurity with vascular endothelial growth factor inhibitors","volume":"88","author":"Mintz-Hittner","year":"2012","journal-title":"Early Hum Dev"},{"key":"R5-20250605","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1007\/s00417-023-06227-6","article-title":"Visual field after anti-vascular endothelial growth factor therapy and laser treatment for retinopathy of prematurity","volume":"261","author":"Obata","year":"2023","journal-title":"Graefe's Archive Clin Exp Ophthalmol"},{"key":"R6-20250605","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.ophtha.2016.04.028","article-title":"Clinical management of recurrent retinopathy of prematurity after intravitreal bevacizumab monotherapy","volume":"123","author":"Mintz-Hittner","year":"2016","journal-title":"Ophthalmology"},{"key":"R7-20250605","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3928\/23258160-20160229-12","article-title":"Very late reactivation of retinopathy of prematurity after monotherapy with intravitreal bevacizumab","volume":"47","author":"Snyder","year":"2016","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R8-20250605","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1097\/IAE.0000000000001996","article-title":"Fluorescein angiographic evaluation of peripheral retinal vasculature after primary intravitreal ranibizumab for retinopathy of prematurity","volume":"39","author":"Harper","year":"2019","journal-title":"Retina"},{"key":"R9-20250605","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.ophtha.2014.05.015","article-title":"Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings","volume":"121","author":"Lepore","year":"2014","journal-title":"Ophthalmology"},{"key":"R10-20250605","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1097\/IAE.0000000000001763","article-title":"Short-term outcomes after intravitreal injections of conbercept versus ranibizumab for the treatment of retinopathy of prematurity","volume":"38","author":"Jin","year":"2018","journal-title":"Retina"},{"key":"R11-20250605","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ophtha.2017.08.005","article-title":"Follow-up to age 4 years of treatment of type 1 retinopathy of prematurity intravitreal bevacizumab injection versus laser: fluorescein angiographic findings","volume":"125","author":"Lepore","year":"2018","journal-title":"Ophthalmology"},{"key":"R12-20250605","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1136\/bjophthalmol-2013-304109","article-title":"Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity","volume":"98","author":"Tahija","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"R13-20250605","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/j.ophtha.2021.05.031","article-title":"International classification of retinopathy of prematurity, third edition","volume":"128","author":"Chiang","year":"2021","journal-title":"Ophthalmology"},{"key":"R14-20250605","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1177\/11206721221076691","article-title":"Comparison of fluorescein angiography findings in stage 3 retinopathy of prematurity in zone II treated with or without anti-VEGF","volume":"32","author":"Vural","year":"2022","journal-title":"Eur J Ophthalmol"},{"key":"R15-20250605","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1007\/s10792-018-01064-7","article-title":"Comparison of fluorescein angiographic findings in type 1 and type 2 retinopathy of prematurity with intravitreal bevacizumab monotherapy and spontaneous regression","volume":"39","author":"Vural","year":"2019","journal-title":"Int Ophthalmol"},{"key":"R16-20250605","doi-asserted-by":"crossref","first-page":"800821","DOI":"10.3389\/fmed.2021.800821","article-title":"Different types of hyperfluorescence observed in post anti-VEGF fluorescein angiographic patterns in retinopathy of prematurity patients","volume":"8","author":"Jin","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"R17-20250605","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jaapos.2011.12.157","article-title":"Fluorescein angiography to estimate normal peripheral retinal nonperfusion in children","volume":"16","author":"Blair","year":"2012","journal-title":"J AAPOS"},{"key":"R18-20250605","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1016\/j.ophtha.2016.06.055","article-title":"Chronic vascular arrest as a predictor of bevacizumab treatment failure in retinopathy of prematurity","volume":"123","author":"Toy","year":"2016","journal-title":"Ophthalmology"},{"key":"R19-20250605","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ajo.2018.09.039","article-title":"A spectrum of regression following intravitreal bevacizumab in retinopathy of prematurity","volume":"198","author":"Chen","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"R20-20250605","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/IAE.0000000000001126","article-title":"Retinal vascular development with 0.312 MG intravitreal bevacizumab to treat severe posterior retinopathy of prematurity: a longitudinal fluorescein angiographic study","volume":"37","author":"Lorenz","year":"2017","journal-title":"Retina"},{"key":"R21-20250605","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1007\/s10792-018-1040-x","article-title":"Efficacy of intravitreal aflibercept monotherapy in retinopathy of prematurity evaluated by periodic fluorescence angiography and optical coherence tomography","volume":"39","author":"Vural","year":"2019","journal-title":"Int Ophthalmol"},{"key":"R22-20250605","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1097\/IAE.0000000000001581","article-title":"Prophylactic peripheral laser and fluorescein angiography after bevacizumab for retinopathy of prematurity","volume":"38","author":"Garcia Gonzalez","year":"2018","journal-title":"Retina"},{"key":"R23-20250605","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1007\/s10792-021-02119-y","article-title":"Angiographic findings in cases with a history of severe retinopathy of prematurity treated with anti-VEGFs: follow-up to age 6 years","volume":"42","author":"Celiker","year":"2022","journal-title":"Int Ophthalmol"},{"key":"R24-20250605","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jcjo.2020.05.017","article-title":"Fluorescein angiographic features post-intravitreal bevacizumab for retinopathy of prematurity: can they support rescue laser photocoagulation to the avascular retina","volume":"55","author":"Gonzalez","year":"2020","journal-title":"Can J Ophthalmol"},{"key":"R25-20250605","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/IAE.0000000000000380","article-title":"Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between Ranibizumab and Bevacizumab","volume":"35","author":"Chen","year":"2015","journal-title":"Retina"},{"key":"R26-20250605","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/IAE.0b013e318275394a","article-title":"Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5 years of follow-up","volume":"33","author":"Mart\u00ednez-Castellanos","year":"2013","journal-title":"Retina"},{"key":"R27-20250605","doi-asserted-by":"crossref","first-page":"F327","DOI":"10.1136\/archdischild-2012-302365","article-title":"Serious adverse events and visual outcomes of rescue therapy using adjunct bevacizumab to laser and surgery for retinopathy of prematurity. The Indian Twin Cities Retinopathy of Prematurity Screening database Report number 5","volume":"98","author":"Jalali","year":"2013","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"R28-20250605","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/archophthalmol.2012.592","article-title":"Reactivation of retinopathy of prematurity after bevacizumab injection","volume":"130","author":"Hu","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"R29-20250605","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/IAE.0000000000000578","article-title":"Reactivation of retinopathy of prematurity after ranibizumab treatment","volume":"35","author":"Wong","year":"2015","journal-title":"Retina"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004032","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T17:02:12Z","timestamp":1749142932000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004032","relation":{},"ISSN":["0275-004X"],"issn-type":[{"type":"print","value":"0275-004X"}],"subject":[],"published":{"date-parts":[[2024,5]]}}}